This company has been acquired
GreenLight Biosciences Holdings Crecimiento futuro
Future controles de criterios 2/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for GreenLight Biosciences Holdings.
Información clave
-1.0%
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 24.8% |
| Tasa de crecimiento de los ingresos | 70.7% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 22 Jul 2023 |
Actualizaciones recientes sobre el crecimiento futuro
No hay actualizaciones
Recent updates
GreenLight Biosciences cutting 25% of staff as part of realignment
Oct 12GreenLight Biosciences launches $109M in financing
Aug 12GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccine
Aug 01GreenLight Biosciences: Synthesizing Cell-Free RNA
Apr 05Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2024 | 22 | -161 | -166 | N/A | 1 |
| 12/31/2023 | N/A | -166 | -177 | N/A | 1 |
| 3/31/2023 | 10 | -157 | -146 | -118 | N/A |
| 12/31/2022 | 7 | -167 | -163 | -137 | N/A |
| 9/30/2022 | 4 | -163 | -164 | -137 | N/A |
| 6/30/2022 | 3 | -154 | -143 | -122 | N/A |
| 3/31/2022 | 2 | -129 | -131 | -120 | N/A |
| 12/31/2021 | 2 | -112 | -107 | -92 | N/A |
| 9/30/2021 | 1 | -86 | -98 | -84 | N/A |
| 6/30/2021 | 2 | -89 | -80 | -68 | N/A |
| 3/31/2021 | 2 | -75 | -70 | -58 | N/A |
| 12/31/2020 | 2 | -53 | -57 | -47 | N/A |
| 12/31/2019 | 3 | -37 | -28 | -26 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: GRNA is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: GRNA is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: GRNA is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: GRNA's revenue (70.7% per year) is forecast to grow faster than the US market (7.4% per year).
Ingresos de alto crecimiento: GRNA's revenue (70.7% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if GRNA's Return on Equity is forecast to be high in 3 years time